Celon Pharma SA (CLN) AI Stock Analysis

• Market Cap: €1.23B
• Dividend Yield: 0.35%
• Average Volume (3M): 15.76K
• Price to Earnings (P/E): 74.9
• Beta (1Y): 0.39
• Revenue Growth: 47.79%
• EPS Growth: N/A
• Country: PL
• Employees: 562
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.62
• Shares Outstanding: 53,856,500
• 10 Day Avg. Volume: 10,435
• 30 Day Avg. Volume: 15,756
• PEG Ratio: -2.02
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 7.86
• P/FCF Ratio: -40.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €21.01
• Price Target Upside: -7.84% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: zł21.00 ▼(-7.89% Downside)

Celon Pharma SA's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, particularly in profitability and cash flow management, which are reflected in the low financial performance score. The technical analysis indicates bearish momentum, with the stock trading below key moving averages and showing signs of being oversold. The valuation suggests potential overvaluation, further contributing to the cautious outlook.

Celon Pharma SA Business Overview & Revenue Model

Company Description

Celon Pharma SA (CLN) is a biotechnology company based in Poland that focuses on the development and commercialization of innovative therapies for cancer and other serious diseases. The company operates primarily in the pharmaceutical sector, specializing in the research, development, and production of both proprietary and partnered drug candidates. Celon Pharma's core products include novel small molecules and biologics aimed at targeting specific pathways involved in cancer progression and treatment resistance.

How the Company Makes Money

Celon Pharma generates revenue primarily through the development and sale of its pharmaceutical products, as well as through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. Key revenue streams include sales of approved therapies, milestone payments received from partners during the drug development process, and royalties on product sales from partnered products. Significant collaborations with larger pharmaceutical companies provide additional funding and resources, contributing to the company's financial stability and growth potential.

Celon Pharma SA Financial Statement Overview

Summary

Celon Pharma SA faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite a strong gross profit margin and low leverage, the company struggles with negative revenue growth and profitability metrics, indicating operational difficulties. The balance sheet is stable with low debt levels, but the negative return on equity reflects inefficiencies in generating shareholder value.

Income Statement

Celon Pharma SA has experienced declining revenue growth, with a negative growth rate of -2.59% in the latest year. The gross profit margin remains relatively strong at 64.23%, but the company is struggling with profitability, as indicated by a negative net profit margin of -19.50% and a negative EBIT margin of -20.89%. The EBITDA margin is positive at 8.47%, showing some operational efficiency, but overall, the income statement reflects challenges in achieving profitability.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.038, indicating conservative leverage. However, the return on equity is negative at -7.74%, reflecting challenges in generating returns for shareholders. The equity ratio is not explicitly calculated, but the company maintains a strong equity base relative to its assets.

Cash Flow

The cash flow statement reveals negative operating cash flow and free cash flow, with a free cash flow growth rate of 3.40%. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is positive at 3.01, suggesting some ability to cover net losses with free cash flow, but overall cash flow management needs improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	193.92M	176.62M	213.92M	161.91M	196.09M	157.45M
Gross Profit	120.99M	113.45M	147.10M	95.45M	134.37M	107.26M
EBITDA	1.18M	14.96M	32.71M	9.32M	27.81M	30.37M
Net Income	-68.60M	-34.45M	-28.12M	-39.28M	-11.61M	-917.00K
Balance Sheet
Total Assets	482.63M	543.79M	569.31M	608.93M	707.14M	703.64M
Cash, Cash Equivalents and Short-Term Investments	38.98M	56.52M	114.54M	164.62M	227.55M	43.98M
Total Debt	19.88M	16.93M	25.59M	26.82M	14.92M	25.48M
Total Liabilities	97.52M	98.59M	123.75M	129.29M	153.14M	268.97M
Stockholders Equity	385.11M	445.21M	445.56M	479.65M	554.00M	344.53M
Cash Flow
Free Cash Flow	-53.44M	-34.13M	-41.13M	-38.61M	2.60M	-28.26M
Operating Cash Flow	-9.38M	-11.34M	-8.31M	-4.70M	43.95M	70.90M
Investing Cash Flow	-2.79M	-7.49M	-21.64M	-31.47M	-121.05M	-98.53M
Financing Cash Flow	-10.58M	13.32M	-20.59M	-28.72M	180.91M	4.25M

Celon Pharma SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CLN, the sentiment is Positive. The current price of 22.8 is above the 20-day moving average (MA) of 22.02, above the 50-day MA of 22.56, and below the 200-day MA of 23.88, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 61.63 is Neutral, neither overbought nor oversold. The STOCH value of 80.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:CLN.

Celon Pharma SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLV	59 Neutral	€679.15M	1,434.11	―	―	14.10%	-99.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLN	46 Neutral	€1.23B	74.93	―	0.35%	47.79%	―
MAB	46 Neutral	€143.04M	―	-57.55%	―	-74.16%	-192.42%
CTX	44 Neutral	€210.09M	―	-83.02%	―	-40.45%	27.53%
RVU	38 Underperform	€655.46M	―	-80.59%	―	15.45%	-25.81%